PBLS Parabilis Medicines, Inc.

CIK 0001657677 3 ready 8-Ks latest August 25, 2026, 4:10 PM ET RSS · JSON

Activity: ELEVATED 2 filings / 30d vs 0 baseline

Ready 8-Ks 3

Latest filing August 25, 2026, 4:10 PM ET

Top materiality 0.85

Event mix leadership ×1 · earnings ×1 · other_material ×1

Sentiment 2 pos · 0 neg · 1 neu

Recent 8-K filings for PBLS

Highest-materiality recent filing

Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B

August 13, 2026, 7:19 AM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.
Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.

August 25, 2026, 4:10 PM ET leadership materiality 0.30 neutral item 5.02 item 7.01 item 9.01

Parabilis Medicines appoints Craig Tendler to board as independent Class II director

Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.
August 13, 2026, 7:19 AM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B

Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.
June 11, 2026, 4:12 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 5.03 item 9.01 ◈ Governance Changes ×2◈ Equity Issuances◈ Material Agreements

Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement

Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.

Max materiality 0.85 · Median 0.75 · Most common event leadership

2 positive 0 negative 1 neutral